Posted by Michael Wonder on 07 May 2017
European Commission approves Keytruda (pembrolizumab) for patients with relapsed or refractory classical Hodgkin lymphoma who failed autologous stem cell transplant and brentuximab vedotin or who are transplant ineligible and have failed brentuximab vedotin
5 May 2017 - First approval for Keytruda in a hematologic malignancy in the EU.
Merck today announced that the European Commission has approved Keytruda (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant and brentuximab vedotin (BV), or who are transplant-ineligible and have failed BV.
The approval allows marketing of Keytruda in all 28 EU member states plus Iceland, Lichtenstein and Norway, at the approved dose of 200 mg every three weeks until disease progression or unacceptable toxicity.
